A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)

Name: A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)
Published: 2024
License: Public Domain

Pfizer · 2024

ClinicalTrials.gov · Datasets · License: Public Domain · 2024

Open Source ↗

multiple-myeloma

multiple myeloma, elranatamab, pf-06863135, iberdomide, relapsed, refractory, rrmm, bcma, magnetismm, bispecific antibody, cc-220, interventional

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)

Related documents